For patients with CDX2 status available, 21% had a BRAF V600E mutation (BRAFmut), 41% a KRAS mutation (KRASmut), 8% were MSI high (MSI-H), and 38% double (KRAS and BRAF) wild-type tumor (Table 1, Figure 3A). This evidence concerns the gene KRAS and neoplasm.